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Abstract
Background: The total effect of a medication is the sum of its drug effect, placebo effect (meaning response), and
their possible interaction. Current interpretation of clinical trials’ results assumes no interaction. Demonstrating such
an interaction has been difficult due to lack of an appropriate study design.
Methods: 180 adults were randomized to caffeine (300 mg) or placebo groups. Each group received the assigned
intervention described by the investigators as caffeine or placebo, in a randomized crossover design. 4-hour-area-
under-the-curve of energy, sleepiness, nausea (on 100 mm visual analog scales), and systolic blood pressure levels
as well as caffeine pharmacokinetics (in 22 volunteers nested in the caffeine group) were determined. Caffeine
drug, placebo, placebo-plus-interaction, and total effects were estimated by comparing outcomes after, receiving
caffeine described as placebo to receiving placebo described as placebo, receiving placebo described as caffeine or
placebo, receiving caffeine described as caffeine or placebo, and receiving caffeine described as caffeine to
receiving placebo described as placebo, respectively.
Results: The placebo effect on area-under-the-curve of energy (mean difference) and sleepiness (geometric mean
ratio) was larger than placebo-plus-interaction effect (16.6 [95% CI, 4.1 to 29.0] vs. 8.4 [-4.2 to 21.0] mm*hr and 0.58
[0.39 to 0.86] vs. 0.69 [0.49 to 0.97], respectively), similar in size to drug effect (20.8 [3.8 to 37.8] mm*hr and 0.49
[0.30 to 0.91], respectively), and its combination with the later was larger than total caffeine effect (29.5 [11.9 to
47.1] mm*hr and 0.37 [0.22 to 0.64]). Placebo-plus-interaction effect increased caffeine terminal half-life by 0.40
[0.12 to 0.68] hr (P = 0.007).
Conclusions: Drug and placebo effects of a medication may be less than additive, which influences the
interpretation of clinical trials. The placebo effect may increase active drug terminal half-life, a novel mechanism of
placebo action.
Trial Registration: ClinicalTrials.gov identification number - NCT00426010.
Background
The placebo effect has been utilized in medical practice
since antiquity and continues to be commonly used [1].
Recent systematic reviews [2,3] doubted the existence
and clinical importance of a placebo effect despite evi-
dence to the contrary [4-7], and more studies have been
advocated to investigate its underlying mechanism(s)
and clinical applications [8].
Comparing changes over time in the placebo arm of a
clinical trial doesn’t separate the placebo effect (meaning
response) [4] from methodological factors such as
regression to the mean, natural course, and the
Hawthorne effect, and thus exaggerates the placebo
effect [9], whereas comparing changes observed in the
placebo arm to a no-treatment-control arm may under-
estimate the placebo effect since enrolled subjects know
that they have only a 50% chance of getting a putatively
active drug [5,10,11]. The balanced placebo design,
where subjects receiving a test substance or a placebo
are either informed that they are receiving this sub-
stance or placebo, or vice versa, can validly investigate
the placebo effect [12] and has been used to study the
placebo effect of several substances [13-18] including
caffeine [13]. A modified balanced placebo model that
uses a cross-over rather than parallel design has the
advantage of reducing noise variation and sample size
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Few studies compared sizes of the placebo and drug
components of a given medication effect or addressed
their potential interaction [13,19-21]. Current interpreta-
tion of clinical trials assumes that there is no such inter-
action [21,22], and that the difference between
medication and placebo arms represents drug effect
rather than a combination of drug and interaction
effects. Evaluating a potential interaction between drug
and placebo effects allows testing the possibility that a
placebo group may not be a good control group in clini-
cal trials. Several studies have described various pharma-
codynamic effects of placebos [13-18,23], however, the
possibility that the placebo effect may involve modula-
tion of drug bioavailability has not been explored. For
example, it is theoretically possible that the placebo
effect may involve altering gastric emptying, intestinal
transit time, or drug elimination. Evaluating such possi-
bility may provide insight into the mechanism of pla-
cebo and interaction effects as well as an objective
outcome measure of the placebo effect.
Using a novel cross-over balanced placebo design, we
measured the placebo effect on continuous and binary
scales to: 1) explore potential interaction of drug and
placebo effects by comparing the difference between
receiving placebo described as caffeine or as placebo
(placebo effect) to the difference between receiving caf-
feine described as caffeine or as placebo (placebo+inter-
action effect) and by comparing measured total
medication effect to the sum of drug and placebo
effects, 2) estimate the relative size of the placebo effect,
and 3) explore the placebo effect on caffeine pharmaco-
kinetics. Healthy subjects and caffeine were selected
because of expected familiarity of caffeine effects to
volunteers and of its safety profile as well as for ethical
reasons, since the study design includes deception. We
were able to measure an important placebo effect both
on continuous and binary scales. Further, we found that
the drug and placebo effects are less than additive and
that the placebo effect may be due in part to modulation
of the bioavailability of the active drug.
Methods
Study design
Participants were block-randomized (block size of four)
to one of two randomized cross-over studies, one using
caffeine described as caffeine or placebo and one using
placebo described as placebo or caffeine. A 14 hour
pharmacokinetics study was nested in the caffeine cross-
over study. The wash-out time between the two periods
of each balanced randomized cross-over study was 48
hours to allow for clearance of plasma caffeine [24] and
most of caffeine (and caffeine withdrawal) effects [25],
and minimize the occurrence of intra-subject differ-
ences. Balanced design was used to eliminate any differ-
ential residual carryover effect. There was no changes to
methods after study commencement.
Participants
Eligibility criteria for participants included an age of 18
to 50 years; being healthy, non-smoker, medication-free
for one week, and able to reproducibly express oneself
using a 100 mm visual analog scale (VAS); and daily caf-
feine consumption between 100 to 300 mg. The first
was assessed by requesting participants to complete 7
VASs (on restlessness, irritability, flushing, headache,
energy, sleepiness, and nausea) before and after obtain-
ing their screening vital signs and without their knowl-
edge of going to be retested. A difference of more than
10 mm on more than one VAS resulted in exclusion.
The range of daily caffeine consumption was selected to
minimize caffeine withdrawal symptoms and adverse
effects (in caffeine-naïve subjects) and was estimated
using the “Caffeine Content of Foods and Drugs” http://
www.cspinet.org/new/cafchart.htm.
The study was conducted at the King Faisal Specialist
Hospital and Research Center (KFSH & RC), Riyadh in
February 2007 through February 2009, from 8-9 am to
12-1 pm. It followed published ethical guidelines on
deception use in clinical research [7,8,22] and was
approved by the Research Ethics Committee of KFSH &
RC. All participants gave written consent being
informed that the study is designed to compare the
effects of capsules containing placebo or 300 mg caffeine
(equivalent to 3 cups of brewed coffee), that the study
aims to determine how much of the observed changes is
not related to caffeine but to the placebo effect, and that
they have a 50/50 chance of receiving a placebo or caf-
feine. They were given the choice to participate in the
main 4-hour study or an extended 14-hour sub-study,
and were compensated based on the Wage-Payment
model [26]. At the completion of the entire study, and
after obtaining their monetary compensation, they were
contacted for briefing and a delayed consent, which was
obtained from all the 95 contactable participants. None
indicated that they have guessed the actual study aims.
No adverse events (other than nausea) were noted.
Interventions
Participants were requested to abstain from smoking
and drinking alcohol for 2 days and from caffeine-con-
taining beverages or food for 16 hours, before and
throughout each study period, to fast from 9 pm, and to
sleep for at least 8 hours.
To enhance the placebo effect, caffeine effects (and
placebo-no-effect) were emphasized just before
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statement to that effect (available in the supplement).
Participants assigned to caffeine received 300 mg caf-
feine twice, 48 hours apart, one time dispensed from a
bottle labelled “caffeine” and one time from a bottle
labelled “placebo” in a random fashion. Participants
assigned to placebo received placebo twice, 48 hours
apart, one time dispensed from a bottle labelled “caf-
feine” and one time from a bottle labelled “placebo” in
a random fashion. Caffeine and placebo were adminis-
tered in the form of 2 capsules with 250 ml of water at
ambient temperature, 15 to 30 minutes after a standar-
dized light breakfast. Participants then abstained from
food for four hours and remained ambulatory or seated
upright until the end of the study. To enhance blinding
and verify compliance, blood was drawn via intravenous
cannula from all participants for caffeine level before
and 3 hours after capsules’ administration. For the
14-hour sub-study, additional blood samples were
obtained at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 4, 6,
8, 10, 12, and 14 hours, and participants received stan-
dardized lunch and dinner that were the same in the
two periods.
Outcomes
Measurements were obtained before, and 0.5, 1.0, 1.5,
2.0, 2.5, 3.0, and 4.0 hours after intervention, in the
following order: systolic blood pressure; VAS for energy,
sleepiness, and nausea; and binary data for not-
energetic, sleepy, and nauseated. Levels of energy, sleepi-
ness, and nausea were self-measured on a 100 mm VAS
anchored by word descriptors at each end (not at all,
very). Caffeine levels were blindly measured by a locally-
validated, modified high performance liquid chromato-
graphy assay [27]. The assay has a linear range of 0.05
to 20 μg/ml and an inter-run coefficient of variation and
bias of ≤6.0% and ≤7%, respectively. Caffeine was stable
in plasma (≥98%) for at least 12 weeks at -20°C. Plasma
samples of each participant were stored in polypropy-
lene tubes at -20°C, and analyzed together within
6 weeks.
Primary outcomes were 4-hour-area-under-the-curve
(AUC4) of systolic blood pressure and VAS scores on
self-measured energy, sleepiness, and nausea level in an
analysis that was adjusted for baseline (analysis of covar-
iance, ANCOVA). Secondary outcomes were binary
measurements of subjective outcomes and placebo effect
on caffeine pharmacokinetics. There were no changes to
study outcomes after study commencement.
Sample size
The study planned to recruit 90 subjects in each cross-
over study, based on an expected standardized mean dif-
ference of placebo effect on continuous subjective
outcome of 0.36 [2], type I error of 0.05, type II error of
0.1, paired design, and 10% dropout rate.
Randomization
The randomization schedule was generated by one of
the authors (MMH) using a program available on-line
http://www.randomization.com. Group assignment was
concealed before randomization from participants and
study coordinators who enrolled them. Interventions
were assigned to participants by two of the investigators
(MMH and EAG).
Blinding
Study coordinators who collected data were blinded to
study design and participants’ assignments. Caffeine
levels were determined by one of the authors (SA) who
was blinded to study design and participants’ assign-
ment. Participants were deceived as to the true aim of
the study and to their assignment.
Statistical methods
Because of positive skew, the AUC4 values for sleepiness
and nausea levels were analyzed after natural logarith-
mic transformation then back transformed, so that the
difference between the groups is expressed as geometric
means ratio. The ANCOVA model included group and
subjects nested within groups (as appropriate), period,
intervention, and baseline value. Mean percentage of
time participants reported being not-energetic, sleepy,
or nauseated was evaluated by the t test. Analyses were
conducted by one author (MMH) with SPSS for Win-
dows software (release 16.0.0, 2007. SPSS Inc., Chicago,
ILL, USA) and SAS for Windows software (version 9.2,
SAS Institute Inc., Cary, NC, USA). 2-tailed p values are
reported unless indicated otherwise.
Model
We assumed that outcome measures associated with
receiving placebo described as placebo represent base-
line value, including non-specific changes, outcome
measures associated with receiving placebo described as
caffeine represent placebo effect + baseline value, out-
come measures associated with receiving caffeine
described as placebo represent drug effect + baseline
value, and outcome measures associated with receiving
caffeine described as caffeine represent drug effect +
placebo effect + interaction effect (drug effect * placebo
effect) + baseline value. Drug effect was estimated by
comparing receiving caffeine described as placebo to
receiving placebo, described as placebo, placebo effect
by comparing receiving placebo described as caffeine to
receiving placebo described as placebo, placebo+interac-
tion effect by comparing receiving caffeine described as
caffeine to receiving caffeine described as placebo, and
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caffeine to receiving placebo described as placebo. Total
effect would include drug and placebo effects and their
interaction. The model is presented in Figure 1.
Results
We screened 287 volunteers and found 214 eligible.
Ineligibility was related to medical history (17), blood
test results (12), daily caffeine intake (11), heavy smok-
ing (6), and education level/VAS test (27). 34 of the 214
eligible volunteers did not show up for the study, thus
180 were equally randomized to caffeine or placebo
cross-over arms. We excluded from analysis participants
who later withdrew from the study (3 randomized to
placebo, 2 to caffeine) or did not adequately abstain
from caffeine (baseline caffeine levels in the study peri-
ods differed by ≥1 μg/ml (2 randomized to placebo and
5 to caffeine). A flow chart is presented in Figure 2.
S t u d yc o o r d i n a t o r sg u e s s e dt h a t5 2 % ,5 1 % ,4 1 % ,a n d
44% of participants who received, caffeine described as
caffeine, caffeine described as placebo, placebo described
as placebo, and placebo described as caffeine, respec-
tively, received caffeine; indicating the success of
blinding. Baseline characteristics of study groups are
shown in Table 1.
Placebo effect on subjective endpoints
The estimated drug, placebo, and total effects are pre-
sented in Figure (3A & 3B) and Table 2. There was sig-
nificant placebo effect on energy level, and placebo
effect and placebo+interaction effect on sleepiness level.
The placebo effect on energy and sleepiness levels and
placebo+interaction effect on sleepiness level were still
significant using Wilcoxon Signed Ranks test without
adjustment for baseline (P = 0.03, P = 0.01, and P =
0.03, respectively), indicating robustness of the results.
There was significant correlation between placebo or
placebo+interaction effects on energy and sleepiness
(placebo effect: r = -0.62, p < 0.001; rho = -0.64, p <
0.001 and placebo+interaction effect: r = -0.62, p <
0.001; rho = -0.58, p < 0.001). There was no significant
placebo or placebo+interaction effect on nausea.
Figure (3C & 3D) depicts unadjusted mean (SE) VAS
scores of energy and sleepiness determined over 4 hours
after intervention. Participants also provided binary
answers about feeling not-energetic, sleepy, or
Figure 1 Model of drug and placebo effects and their interaction. Total effect is inferred from the difference between received caffeine
described as caffeine and received placebo described as placebo. Drug effect is inferred from the difference between received caffeine
described as placebo and received placebo described as placebo. The model predicts two kinds of measured “placebo effect": a) PLACEBO-1 is
inferred from the difference between received placebo described as caffeine and received placebo described as placebo, which contains the
placebo effect only, and b) PLACEBO-2 is inferred from the difference between received caffeine described as caffeine and received caffeine
described as placebo, which contains the placebo effect and the interaction effect. Note that PLACEBO-1 is depicted here larger than PLACEBO-2
and that the total effect is smaller than the combination of the drug and placebo effects (as measured by PLACEBO-1) to indicate that the drug
and placebo effects are less than additive.
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hours after intervention (Figure (3E &3F)). The binary
data were consistent with the continuous data. Using
percentage of time symptoms were reported over 4
hours as a summary measure, there was significant pla-
cebo effect on feeling not-energetic and sleepy (Table 3)
that was still significant using Wilcoxon Signed Ranks
test (1-tailed P = 0.006 and P = 0.04, respectively). The
placebo+interaction effect was not significant.
The placebo and drug effects were comparable in size
on the three subjective endpoints (Tables 2 &3). Head
to head comparison of the ANCOVA-adjusted means of
the placebo and drug effects, using t test did not show a
significant difference (p = 0.66 to 0.75).
Interaction between drug and placebo effects
As shown in Table 2, the placebo effect was larger than
the placebo+interaction effect on energy and sleepiness
levels, and the combination of drug and placebo effects
was larger than the total effect. Further, while the pla-
cebo effect was significant on binary endpoints, the
placebo+interaction effect was not (Table 3). We also
estimated the drug+interaction effect by comparing
receiving caffeine described as caffeine to receiving pla-
cebo described as caffeine, using ANCOVA. The drug
+interaction effect was not significant on energy level
11.3 [CI, -4.3 to 27.0] mm*hr, p = 0.15) and of border-
line significance on sleepiness level (geometric mean
ratio 0.56 [CI, 0.32 to 1.00), p = 0.05). The data com-
bined strongly suggest the presence of a negative inter-
action between caffeine drug and placebo effects.
Drug and placebo effects followed similar time course
w i t hap e a ka t2t o2 . 5h o u r s ,w h e r e a s ,t h ei n t e r a c t i o n
effect on sleepiness level appeared to increase over the
study period (Figure (3A &3B)).
Placebo effect on objective outcomes
We examined whether caffeine plasma level depends
upon whether participants knew they were getting caf-
feine. We conducted a 14 hour bioavailability study on
22 participants nested in the 83 who received caffeine
described as caffeine or as placebo in a balanced
Figure 2 Flow diagram of study procedures. *Excluded because of failure to abstain from caffeine as reflected on baseline level.
Hammami et al. Trials 2010, 11:110
http://www.trialsjournal.com/content/11/1/110
Page 5 of 10randomized cross-over design, under controlled food
and fluid intake. Mean plasma caffeine levels before and
after natural logarithmic transformation are shown in
Figure (4A &4B). They were lower in the terminal part
of the curve after receiving caffeine described as placebo
compared to receiving caffeine described as caffeine.
Caffeine pharmacokinetics is shown in Table 4. Using
ANOVA (model included group, subjects nested in
groups, period, and intervention), there was no signifi-
cant difference in maximum measured plasma level or
its time. However, caffeine AUC was significantly lower
and caffeine terminal half-life was significantly shorter
after receiving caffeine described as placebo. These dif-
ferences continued to be significant using ANOVA after
logarithmic transformation of data or Wilcoxon Signed
Ranks test (Table 4). There was no significant period
(p = 0.45 to 0.80) or group effect (p = 0.47 to 0.79).
Furthermore, there was a significant difference in mean
3-hour caffeine level (Table 1) in the entire group of 83
participants who received caffeine when caffeine was
described as caffeine compared to when it was described
as placebo (0.3 [CI, 0.04 to 0.57] μg/ml, p = 0.02).
We did not find a significant placebo effect or
placebo+interaction effect on systolic blood pressure
despite the presence of a clear drug effect (Table 2 and
Figure 4(C)).
Discussion
Our study design allowed dissecting total caffeine effect
into its components: drug, placebo, and interaction
effects. It was argued that if a placebo effect exists it
would be of negligible importance [2]. We found that
Table 1 Baseline characteristics of study participants
Characteristics Caffeine Group*
(N = 83)
Placebo Group†
(N = 85)
Both Groups
(N = 168)
Age – mean (SD), yr 30.6 (6.6) 28.3 (5.7) 29.4 (6.4)
Sex – no. (%)
Female 10 (12) 17 (20) 27 (16)
Male 73 (88) 68 (80) 141 (84)
Completed education – no. (%)
High school 15 (18) 7 (8) 22 (13)
College 44 (53) 54 (64) 98 (58)
University 24 (29) 24 (28) 48 (29)
Caffeine consumption – no. (%)
100-149 mg/dy 28 (34) 23 (27) 51 (30)
150-199 mg/dy 28 (34) 24 (28) 52 (31)
200-249 mg/dy 15 (18) 22 (26) 37 (22)
250-300 mg/dy 12 (14) 16 (19) 28 (17)
Occupational Status – no. (%)
Professional, technical, managerial 17 (21) 19 (22) 36 (22)
Clerical, sales 24 (29) 32 (38) 56 (34)
Service 22 (27) 25 (29) 47 (28)
Agricultural, fishery related 10 (12) 1 (1) 11 (7)
Students 6 (7) 8 (9) 14 (8)
Unemployed 3 (3) 0 (0) 3 (2)
Race or ethnic group – no. (%)
Saudi 3 (4) 9 (11) 12 (7)
Arab, non-Saudi 14 (17) 11 (13) 25 (15)
Asian 66 (80) 65 (76) 131(78)
Overt Covert Overt Covert
Caffeine level – mean (SD), μg/ml
Baseline 0.26 (0.43) 0.20 (0.34) 0.30 (0.56) 0.29 (0.35)
3-hour 9.38 (2.86) 9.08 (2.77) 0.17 (0.25) 0.18 (0.24)
Energy level – mean (SD), mm‡ 71 (25) 70 (24) 74 (19) 74 (20)
Sleepiness level – mean (SD), mm‡ 19 (22) 22 (26) 20 (25) 20 (20)
Nausea level – mean (SD), mm‡ 7 (14) 6 (13) 8 (18) 9 (15)
Systolic blood pressure – mean (SD), mm Hg 121 (14) 122 (13) 121 (12) 122 (12)
*Received 300 mg caffeine twice, described as caffeine (overt) or as placebo (covert) in a balanced randomized cross-over design. †Received placebo twice,
described as placebo (overt) or as caffeine (covert) in a balanced randomized cross-over design. ‡ Measured on 100 mm visual analogue scale.
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Page 6 of 10Figure 3 Self-reported energy and sleepiness levels on continuous and binary scales over four hours after intervention. A and B: Time
course of estimated unadjusted total effect (closed diamond), drug effect (closed squares), placebo effect (closed triangles), and interaction
effect (closed circles with interrupted line) on VAS scores of energy and sleepiness level, respectively. C and D: Mean unadjusted VAS Scores for
energy and sleepiness, respectively. E and F: Mean unadjusted percentage of time, lack of energy and sleepiness, respectively, were reported. T
bars indicate standard errors. Squares indicate receiving 300 mg caffeine, described as caffeine (open square with continuous line) or as placebo
(closed square with interrupted line) by 83 subjects in a balanced randomized cross-over design. Triangles indicate receiving placebo described
as placebo (open triangle with continuous line) or as caffeine (closed triangle with interrupted line) by 85 subjects in a balanced randomized
cross-over design. The difference between open squares and open triangles represents the total effect. The difference between closed squares
and open triangles represents the drug effect. The difference between open triangles and closed triangles represents the placebo effect. The
difference between open squares and closed squares represents the placebo+interaction effect.
Table 2 Drug, placebo, placebo+interaction, and total effects on systolic blood pressure, energy, sleepiness, and
nausea levels
Drug
Effect
Placebo
Effect
Placebo+
interaction
Effect
Total
Effect
Energy level
(mm*hr)
20.8 [3.8 to 37.8]
P = 0.02
16.6 [4.1 to 29.0]
P = 0.01
8.4 [-4.2 to 21.0]
P = 0.19
29.5 [11.9 to 47.1]
P = 0.001
Sleepiness level
(ratio)
0.49 [0.30 to 0.91]
P = 0.005
0.58 [0.39 to 0.86]
P = 0.007
0.69 [0.49 to 0.97]
P = 0.03
0.37 [0.22 to 0.64]
P < 0.0001
Nausea level
(ratio)
1.59 [1.00 to 2.52]
P = 0.05
1.43 [0.91 to 2.27]
P = 0.12
1.04 [0.74 to 1.47]
P = 0.82
1.46 [0.91 to 2.34]
P = 0.12
Systolic blood pressure
(mm Hg*hr)
28.4 [20.5 to 36.4]
P < 0.0001
1.2 [-3.0 to 5.4]
P = 0.57
-0.2 [-4.6 to 4.1]
P = 0.91
29.9 [22.3 to 37.6]
P < 0.0001
Data are adjusted point estimate [95% confidence interval]. Point estimate is the difference between means (systolic blood pressure and energy level s )o rr a t i oo f
geometric means (sleepiness and nausea levels). Drug effect = “receiving caffeine described as placebo” mean - “receiving placebo described as placebo” mean
or ratio of their geometric means. Placebo effect = “receiving placebo described as caffeine” mean - “receiving placebo described as placebo” mean or ratio of
their geometric means. Placebo+interaction effect = “receiving caffeine described as caffeine” mean - “receiving caffeine described as placebo” mean or ratio of
their geometric means. Total effect = “receiving caffeine described as caffeine” mean - “receiving placebo described as placebo” mean or ratio of their geometric
means. Unadjusted mean(SE) of energy (mm*hr), sleepiness (mm*hr), nausea (mm*hr), and systolic blood pressure (mm Hg*hr) levels were respectively, 293.5
(10.1), 70.3(8.5), 23.8(4.3), and 499(5.2) when caffeine was described as caffeine; 284.9(8.9), 83.5(8.7), 23.8(4.7), and 500(5.1) when caffeine was described as
placebo; 275.2(9.2),114.8(10.5), 23.7(5.1), and 469(4.3) when placebo was described as placebo; and 291.8(6.6), 91.1(8.3), 24.1(3.7), and 471(4.7) when placebo was
described as caffeine.
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consistent with a recent analysis of 37 trials in which
patients were randomized to no treatment, placebo, or
active intervention, that found the relative contributions
of spontaneous improvement and of placebo to that of
active interventions, 24% and 20%, respectively [23]; and
the observation that patients’ belief [28] and preference
[29] regarding treatment assignment were clinically
important; and suggesting the worth of investing more
time and effort on maximizing placebo benefits in
clinical practice. The observed placebo effect size may
explain why generic drug formulations that pass rigor-
ous bioequivalence studies are seen as less potent (not
more potent) than their more expensive branded coun-
terparts [30,31].
The placebo effect was larger when measured using
placebo (described as caffeine or as placebo) compared
to when measured using caffeine (described as caffeine
or as placebo), the combination of placebo and drug
effects was larger than total effect, and the combination
Table 3 Drug, placebo, placebo+interaction, and total effects on self-classification as not-energetic, sleepy, and
nauseated.
Drug
Effect
Placebo
Effect
Placebo+
interaction
Effect
Total
Effect
Not-energetic -6.3 [-15.4 to 2.8]
P = 0.09
-7.9 [-14.5 to -1.3]
P = 0.01
-2.4 [-7.8 to 3.0]
P = 0.19
-8.6 [-17.5 to -1.7]
P = 0.03
Sleepy -12.9 [-23.1 to -2.6]
P = 0.007
-7.9 [-16.4 to 0.0]
P = 0.03
-3.1 [-10.4 to 4.1]
P = 0.19
-16.0 [-26.2 to -5.8]
P = 0.001
Nauseated -2.1 [-8.1 to 3.8]
P = 0.24
-3.4 [-8.8 to 1.9]
P = 0.10
1.2 [-3.8 to 6.3]
P = 0.32
-0.9 [-7.3 to 5.5]
P = 0.39
Data are mean [95% confidence interval] percentage of time the particular symptom was reported over 4 hours after intervention.
P values are from 1-tailed t test. Drug effect = “receiving caffeine described as placebo” mean - “receiving placebo described as placebo” mean. Placebo effect =
“receiving placebo described as caffeine” mean - “receiving placebo described as placebo” mean. Placebo+interaction effect = “receiving caffeine described as
caffeine” mean - “receiving caffeine described as placebo” mean. Total effect = “receiving caffeine described as caffeine” mean - “receiving placebo described as
placebo” mean. Mean(SE) percentage of time not-energetic, sleepy, or nauseated, respectively, were reported over 4 hours after intervention were 10.0(2.6), 15.9
(3.2), and 7.6(2.1) when caffeine was described as caffeine; 12.4(2.9), 19.0(3.3), and 6.3(1.7) when caffeine was described as placebo; 18.6(3.6), 31.9(4.1), and 8.5
(2.4) when placebo was described as placebo; and 10.8(2.7), 24.0(3.5), and 5.0(1.1) when placebo was described as caffeine.
Figure 4 Placebo effect on caffeine plasma levels and systolic blood pressure.A&B :M e a np l a s m ac a f f e i n el e v e l so v e r1 4h o u r sa f t e r
administration of caffeine to 22 participants in a balanced cross-over design before (A) and after natural logarithmic transformation (B). C:
Systolic blood pressure over four hours following intervention. Squares indicate receiving 300 mg caffeine described as caffeine (open square
with continuous line) or as placebo (closed square with interrupted line). Triangles indicate the administration of placebo described as placebo
(open triangle with continuous line) or as caffeine (closed triangle with interrupted line). T bars indicate standard errors.
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Page 8 of 10of drug and interaction effects was smaller than drug
effect. Although these differences were not statistically
significant, together they suggest that caffeine drug and
placebo effects are less than additive. In previous studies
that used a balanced placebo design, caffeine placebo
[32] and alcohol placebo [20] effects were also more
readily seen using placebo than using the active sub-
stance. Further, a neuro-imaging study showed that
alcohol intoxication and expectancy have opposite
effects on neuronal activation [14]. The possibility that
there may be an interaction between placebo and drug
effects has important implications. The difference
between drug and placebo arms in clinical trials may
represent not only drug pharmacological effect but also
an interaction effect and thus may underestimate (if
effects are less than additive) or overestimate (if effects
are more than additive) pharmacological drug effect.
The possibility of less than additive effects may explain
the clinically trivial effect of antidepressants as deduced
from clinical trials [21].
Converging evidence suggests that different mechan-
isms may underlie different placebo effects, for example,
opioid pathways underlie placebo analgesia and dopami-
nergic pathways underlie placebo effect on movement
disorders [7,33]. We tested a priori hypothesis that pla-
cebo effect may influence drug bioavailability. We found
no effect on the rate of caffeine absorption but significant
and unexpected effect on caffeine terminal half-life, and
as a result, caffeine AUC (about 7% increase). In addition
to providing evidence for placebo effect on objective end-
points, this observation presents a novel mechanism of
placebo effect that deserves further studies, and suggests
the importance of blinding in bioequivalence studies that
compare generic to brand drug formulations and in clini-
cal trials with objective endpoints.
Study limitations include intervention’s administration
by an undeceived investigator which may have reduced
the placebo effect. Further, the balanced placebo design
assumes that instructions fully control participants’
beliefs regarding their assignment, which we did not
verify; and is prone to experimental subordination bias
[22], which can inflate the placebo response. However,
the absence of a physician-patient relationship and of
placebo effect on nausea, and the different sizes of the
placebo effect in the two arms of the study suggest that
the effect of such bias would be minimal.
Conclusions
In this large randomized, cross-over balanced placebo
design study, using caffeine as a model drug, we found
that: 1) a significant placebo effect could be measured
on continuous and binary scales, 2) the placebo effect is
similar in size to the drug effect, 3) drug and placebo
effects may be less than additive, and 4) the placebo
effect may be due in part to modulation of drug
metabolism.
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Table 4 Pharmacokinetics of caffeine when described as caffeine or placebo.
Untransformed Log-transformed
AUC14 (μg/
ml*hr)
AUC∞
(μg/ml*hr)
Cmax
(μg/ml)
Tmax
(hr)
t 1/2
(hr)
AUC14
(μg/ml*hr)
AUC∞
(μg/ml*hr)
Cmax
(μg/ml)
t 1/2
(hr)
Described as
Caffeine*
58.4 (4.6) 82.8 (9.6) 7.2 (0.5) 2.9 (0.3) 6.3 (0.5) 4.01 (0.08) 4.30 (0.10) 1.93 (0.07) 1.77 (0.08)
Described as
Placebo*
56.2 (4.3) 77.4 (8.7) 7.1 (0.4) 2.7 (0.2) 5.92 (0.5) 3.97 (0.07) 4.24 (0.10) 1.93 (0.06) 1.71 (0.08)
ANOVA† 2.33
[0.35 to 4.31]
P = 0.02
5.43
[1.62 to 9.23]
P = 0.008
0.06
[-0.25 to 0.37]
P = 0.70
0.22
[-0.33 to 0.77]
P = 0.42
0.40
[0.12 to 0.68]
p = 0.007
1.04
[1.00 to 1.07]
P = 0.05
1.07
[1.02 to 1.11]
P = 0.004
1.00
[0.94 to 1.06]
P = 0.99
1.07
[1.02 to 1.12]
P = 0.01
Wilcoxon
Signed Ranks‡
P = 0.02 P = 0.006 P = 0.61 P = 0.46 P = 0.007
*Data are unadjusted mean (SE) before and after natural logarithmic transformation. †Data are adjusted point estimate [95% confidence interval]. Point estimate
is “receivng caffeine described as caffeine” mean - “receivng caffeine described as placebo” mean (untransformed data) or ratio of their geometric means
(transformed data). The ANOVA model included group, subjects nested in groups, period, and intervention. There was no significant period or group effects (P =
0.45 to 0.80). ‡Comparing “receiving caffeine described as caffeine” to “receiving caffeine described as placebo”. AUC14, area under the plasma concentration-
time curve from time 0 to 14 hour (calculated by linear trapezoidal method); AUC∞, area under the plasma concentration-time curve from time 0 to infinity
(AUC4 + last measured level/terminal rate constant); Cmax and Tmax, maximum measured plasma level and its time; t1/2, plasma half-life (Ln 2/terminal elimination
constant [slope of the linear regression line of natural log-transformed last 6 measurable caffeine levels vs time curve]).
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